决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma.
我们的研究结果共同表明,用组织相关趋化因子受体对 CAR-NK 细胞进行共修饰,对过继性 NK 细胞治疗的影响不止于改善其在肿瘤部位内的迁移与滞留。
多发性骨髓瘤具有骨髓嗜性。组织特异性趋化因子受体可引导过继CAR-NK细胞进入实体瘤及骨髓中的白血病或骨髓瘤。本研究为BCMA CAR-NK-92及原代NK细胞导入野生型CXCR4或功能增强突变体CXCR4 R334X,以响应骨髓趋化因子CXCL12。表达CXCR4后,细胞体外向CXCL12迁移能力提高;此外,CXCR4还增强BCMA CAR-NK细胞杀伤能力,可清除BCMA表达的细胞系及患者骨髓瘤细胞,并加速细胞毒颗粒释放。CXCR4共修饰延长CAR表面表达,增强CAR结合后的ZAP-70募集及信号转导,并提升对抗原的敏感性。令人意外的是,即使没有CXCL12配体刺激,CXCR4也可提供共刺激。结果提示,加入组织相关趋化因子受体对CAR-NK的影响不止于改善迁移和肿瘤内滞留。
Multiple myeloma (MM) is a plasma cell disease with a preferential bone marrow (BM) tropism. Enforced expression of tissue-specific chemokine receptors has been shown to successfully guide adoptively-transferred CAR NK cells towards the malignant milieu in solid cancers, but also to BM-resident AML and MM. For redirection towards BM-associated chemokine CXCL12, we armored BCMA CAR-NK-92 as well as primary NK cells with ectopic expression of either wildtype CXCR4 or a gain-of-function mutant CXCR4 R334X . Our data showed that BCMA CAR-NK-92 and -primary NK cells equipped with CXCR4 gained an improved ability to migrate towards CXCL12 in vitro . Beyond its classical role coordinating chemotaxis, CXCR4 has been shown to participate in T cell co-stimulation, which prompted us to examine the functionality of CXCR4-cotransduced BCMA-CAR NK cells. Ectopic CXCR4 expression enhanced the cytotoxic capacity of BCMA CAR-NK cells, as evidenced by the ability to eliminate BCMA-expressing target cell lines and primary MM cells in vitro and through accelerated cytolytic granule release. We show that CXCR4 co-modification prolonged BCMA CAR surface deposition, augmented ZAP-70 recruitment following CAR-engagement, and accelerated distal signal transduction kinetics. BCMA CAR sensitivity towards antigen was enhanced by virtue of an enhanced ZAP-70 recruitment to the immunological synapse, revealing an increased propensity of CARs to become triggered upon CXCR4 overexpression. Unexpectedly, co-stimulation via CXCR4 occurred in the absence of CXCL12 ligand-stimulation. Collectively, our findings imply that co-modification of CAR-NK cells with tissue-relevant chemokine receptors affect adoptive NK cell therapy beyond improved trafficking and retention within tumor sites.
MEMBER ACCOUNT
登录成功会直接打开下一页。